The Unusual Whales Subversive Democratic Trading ETF is an actively managed equity fund that invests primarily in publicly traded companies that sitting Democratic members of the U.S. Congress and their families have also reported owning through disclosure filings made under the Stop Trading on Congressional Knowledge Act of 2012, commonly called the STOCK Act. Rather than tracking a conventional index, the fund uses those public filings to help shape its portfolio, giving it a distinctive, rules-driven-but-active strategy.
The result is a portfolio heavily skewed toward large-cap U.S. growth companies. Top holdings have typically included NVDA (NVIDIA), MSFT (Microsoft), GOOG (Alphabet), AMZN (Amazon), and AAPL (Apple), alongside names such as Applied Materials, CrowdStrike, Netflix, Philip Morris International, Eli Lilly, and American Express. Sector exposure is dominated by information technology, followed by health care, communication services, consumer cyclical and defensive stocks, financial services, and industrials. Geographically, the fund is almost entirely U.S.-centric, with more than 99% of assets in North America.
Structurally, this means the fund's forward-looking performance potential is closely linked to a concentrated group of mega-cap technology franchises, semiconductors, and AI enablers. Its relatively low number of holdings and top-heavy weighting amplify the influence of its largest positions, while its modest asset base and active rebalancing mean portfolio composition can evolve as new congressional disclosures are filed. The fund carries a net expense ratio of approximately 0.74%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Several upcoming developments could shape the fund's trajectory. First, the earnings and guidance from its largest technology holdings will be a primary catalyst. Companies such as NVIDIA, Microsoft, Alphabet, and Amazon are central to the AI infrastructure build-out, and their commentary on capital expenditure, cloud demand, and semiconductor supply will directly influence the fund's heaviest weights.
Second, the trajectory of interest rates and inflation remains pivotal. Growth equities are particularly sensitive to changes in long-term yields, because their valuations rely heavily on future cash flows. A sustained decline in inflation that allows the Federal Reserve to ease policy would generally be supportive, while sticky inflation or resurgent yields could pressure the fund's growth-heavy positioning.
Third, health care and biotech developments matter for the fund's second-largest sector. Catalysts such as drug approvals, clinical trial results, and policy discussions around drug pricing can move holdings like Eli Lilly and other pharmaceutical and medical-device names.
Fourth, regulatory and trade policy could affect the fund's financial, technology, and consumer holdings. Antitrust scrutiny of large platforms, changes to trade policy affecting semiconductor supply chains, and consumer-credit conditions are all worth monitoring.
Finally, the fund's own rebalancing mechanics are a catalyst. Because it draws on congressional disclosure activity, shifts in what Democratic lawmakers buy or sell can alter portfolio exposure over time, potentially changing the fund's sector and single-stock concentration.
The macro outlook for the fund is intertwined with the broader equity-market cycle and, in particular, with the AI-driven technology supercycle. Sustained enterprise and hyperscaler investment in data centers, chips, and software continues to support demand across the fund's largest sector. However, this same exposure means the fund is vulnerable to any slowdown in AI capital expenditure or a reassessment of technology valuations.
Interest rates are a central macro variable. Lower real yields and easing financial conditions tend to favor the long-duration growth stocks that dominate the portfolio, while a higher-for-longer rate environment could create headwinds. Inflation trends, labor-market strength, and the Federal Reserve's policy path will therefore act as a backdrop for the fund's valuation-sensitive holdings.
Beyond technology, the fund's health care exposure provides exposure to relatively defensive, innovation-driven demand, while its financial-services and consumer holdings tie its fortunes to the health of the U.S. consumer and credit cycle. Because the portfolio is overwhelmingly U.S.-focused, domestic economic growth, corporate earnings, and currency movements affecting multinational revenue are the key macro forces to watch.
Over the long term, the fund's structural positioning aligns with several durable investment themes. The ongoing adoption of artificial intelligence, cloud computing, and advanced semiconductors represents a multi-year technology cycle that underpins the fund's largest holdings. As enterprises digitize operations and invest in AI infrastructure, the companies at the center of that ecosystem may continue to capture a disproportionate share of corporate technology budgets.
Demographic and innovation trends also support the fund's health care exposure, where an aging population and advances in therapeutics and medical devices provide a long-running demand backdrop. The fund's consumer and financial holdings, meanwhile, are tied to the resilience of U.S. household spending and the broader credit cycle.
At the same time, structural risks should be acknowledged. Concentration in a small number of mega-cap technology names increases sensitivity to regulatory action, competitive disruption, and valuation compression. The fund's active, disclosure-driven rebalancing also means its long-term exposure can shift as congressional trading patterns evolve. Investors weighing the future outlook of this ETF should consider both the powerful secular tailwinds behind its technology-heavy portfolio and the concentration and macro sensitivity embedded in its structure.
In my own analysis of funds like this one, I often turn to Tickeron’s AI Trend Prediction Engine to get a clearer sense of potential directional moves. The tool provides forecasts on whether an asset may trend bullish, bearish, or sideways, along with historical context and alerts that help refine timing decisions. It has become a practical addition to my regular review process when evaluating concentrated portfolios such as this.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
NANC moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend. In 12 of 15 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 80%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NANC as a result. In 40 of 55 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for NANC turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 32 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
The 10-day moving average for NANC crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NANC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for NANC entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NANC's RSI Oscillator exited the oversold zone, 17 of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 29 of 31 cases where NANC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where NANC advanced for three days, in 239 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
NANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows